[CAS NO. 1286739-19-2]  FRAX597

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1286739-19-2]

Catalog
HY-15542A
Brand
MCE
CAS
1286739-19-2

DESCRIPTION [1286739-19-2]

Overview

MDLMFCD25976723
Molecular Weight558.10
Molecular FormulaC29H28ClN7OS
SMILESO=C1C(C2=CC=C(C3=CN=CS3)C=C2Cl)=CC4=CN=C(NC5=CC=C(N6CCN(C)CC6)C=C5)N=C4N1CC

For research use only. We do not sell to patients.


Summary

FRAX597 is a potent group I p21-activated Kinases ( PAK s) inhibitor with IC 50 of 8, 13 and 19 nM for PAK1 , 2 and 3 .


IC50 & Target

PAK1

8 nM (IC 50 )

PAK2

13 nM (IC 50 )

PAK3

19 nM (IC 50 )


In Vitro

FRAX597 is determined to be a potent, ATP-competitive inhibitor of group I PAKs (PAK 1-3), with biochemical IC 50 values as follows: PAK1 IC 50 =8 nM, PAK2 IC 50 =13 nM, PAK3 IC 50 =19 nM. The IC 50 toward PAK4, a member of group II PAKs is >10 μM. At a concentration of 100 nM FRAX597 displays a significant (>80% inhibition) inhibitory capacity toward YES1 (87%), RET (82%), CSF1R (91%), TEK (87%), PAK1 (82%), and PAK2 (93%). When measured using the Kinase Glo Assay in the presence of 20 nM protein and 1 μM ATP, FRAX597 displayed an IC 50 value of 48 nM against wild type PAK1, while IC 50 values against the V342F and V342Y PAK1 mutants are higher than 3 μM and 2 μM, respectively [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Analysis of the flux reading for the animals in the two cohorts demonstrates a significantly slower tumor growth rate in FRAX597-treated mice compared with control mice. After 14 days of treatment the animals are sacrificed and the tumors excised and weighed. FRAX597-treated cohort shows significantly lower average tumor weight compared with the control cohort (0.55 g versus 1.87 g, p=0.0001) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 14.29 mg/mL ( 25.60 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7918 mL 8.9590 mL 17.9179 mL
5 mM 0.3584 mL 1.7918 mL 3.5836 mL
10 mM 0.1792 mL 0.8959 mL 1.7918 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: 1.43 mg/mL (2.56 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: 1.43 mg/mL (2.56 mM); Suspended solution; Need ultrasonic

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 1.43 mg/mL (2.56 mM); Clear solution

* All of the co-solvents are available by MCE.